Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR2 | P25025 | 1/20 | 0.53 |
| ▸ | LDHA | P00338 | 1/20 | 0.47 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.46 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.46 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.46 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.45 |
| ▸ | MEN1 | O00255 | 7/20 | 0.45 |
| ▸ | KDM4A | O75164 | 1/20 | 0.45 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.45 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL485570 | 0.81 | KMT2A (0.48) | CXCR2LDHAP2RX1P2RX3P2RX4 | |
| SCHEMBL485240 | 0.81 | KMT2A (0.48) | CXCR2LDHAP2RX1P2RX3P2RX4 | |
| SCHEMBL485241 | 0.81 | KMT2A (0.48) | CXCR2LDHAP2RX1P2RX3P2RX4 | |
| SCHEMBL484914 | 0.80 | KMT2A (0.51) | LDHAP2RX1P2RX3P2RX4P2RX7 | |
| SCHEMBL12706898 | 0.77 | KMT2A (0.44) | LDHAP2RX1P2RX3P2RX4P2RX7 | |
| SCHEMBL485726 | 0.76 | CYP1A1 (0.48) | CXCR2LDHAKMT2AMEN1KDM4A | |
| SCHEMBL27693288 | 0.76 | CXCR2 (0.54) | CXCR2LDHAP2RX1P2RX3P2RX4 | |
| SCHEMBL10719823 | 0.76 | LDHA (0.59) | LDHAP2RX1P2RX3P2RX4P2RX7 | |
| SCHEMBL486080 | 0.76 | KMT2A (0.47) | CXCR2LDHAP2RX1P2RX3P2RX4 | |
| SCHEMBL485239 | 0.74 | KDM4E (0.63) | CXCR2LDHAP2RX1P2RX3P2RX4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2040690-B1 | INHIBITORS OF CXCR2 | SANOFI SA (FR) | 2014-08-06 | — | — | EP | disclosed |
| EP-2040690-B1 | INHIBITORS OF CXCR2 | SANOFI SA (FR) | 2014-08-06 | — | — | EP | disclosed |
| US-8552033-B2 | Inhibitors of CXCR2 | SANOFI (FR) | 2013-10-08 | — | — | US | disclosed |
| US-8552033-B2 | Inhibitors of CXCR2 | SANOFI (FR) | 2013-10-08 | — | — | US | disclosed |
| US-8552033-B2 | Inhibitors of CXCR2 | SANOFI (FR) | 2013-10-08 | — | — | US | disclosed |
| US-20090215827-A1 | INHIBITORS OF CXCR2 | SANOFI-AVENTIS (FR) | 2009-08-27 | — | — | US | disclosed |
| US-20090215827-A1 | INHIBITORS OF CXCR2 | SANOFI-AVENTIS (FR) | 2009-08-27 | — | — | US | disclosed |
| US-20090215827-A1 | INHIBITORS OF CXCR2 | SANOFI-AVENTIS (FR) | 2009-08-27 | — | — | US | disclosed |
| EP-2040690-A1 | INHIBITORS OF CXCR2 | Sanofi-Aventis (FR) | 2009-04-01 | — | — | EP | disclosed |
| WO-2008000407-A1 | INHIBITORS OF CXCR2 | SANOFI-AVENTIS (FR) | 2008-01-03 | — | — | WO | disclosed |
| WO-2008000407-A1 | INHIBITORS OF CXCR2 | SANOFI-AVENTIS (FR) | 2008-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215827-A1 | INHIBITORS OF CXCR2 | CXCR2, CXCR1, CXCR4 | CXCR2 1/4885LDHA 3234/4885P2RX1 45/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.